Literature DB >> 2032376

The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin.

J M McGregor1, J N Barker, D M MacDonald.   

Abstract

The development of cutaneous proliferative lesions following renal transplantation has been well documented in the literature. Those lesions most commonly seen include viral warts, actinic keratoses and basal-cell and squamous-cell carcinomata. More recently it has been suggested that melanocyte proliferation, both benign and malignant, may follow renal transplantation, probably as a result of immunosuppression. We report the case of an identical twin who developed numerous benign melanocytic naevi following renal transplantation; no such proliferation of naevi occurred in his identical sibling.

Entities:  

Mesh:

Year:  1991        PMID: 2032376     DOI: 10.1111/j.1365-2230.1991.tb00325.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  4 in total

1.  The molecular basis of autoantibody pathogenicity.

Authors:  B James
Journal:  J R Soc Med       Date:  1994-12       Impact factor: 5.344

2.  Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults.

Authors:  Emilie Lanoy; Dominique Costagliola; Eric A Engels
Journal:  Int J Cancer       Date:  2010-04-01       Impact factor: 7.396

3.  Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study.

Authors:  I A Bilmon; L J Ashton; R E Le Marsney; A J Dodds; T A O'Brien; L Wilcox; I Nivison-Smith; B Daniels; C M Vajdic
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

4.  Melanoma Risk and Survival among Organ Transplant Recipients.

Authors:  Hilary A Robbins; Christina A Clarke; Sarah T Arron; Zaria Tatalovich; Amy R Kahn; Brenda Y Hernandez; Lisa Paddock; Elizabeth L Yanik; Charles F Lynch; Bertram L Kasiske; Jon Snyder; Eric A Engels
Journal:  J Invest Dermatol       Date:  2015-08-13       Impact factor: 7.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.